BenevolentAI Investor Day Presentation Deck
Benevolent Platform TM: a validated approach
INTERNAL PIPELINE VALIDATION
Pipeline generated from the
Benevolent Platform™
✓ One asset in Phase II, 3 assets in
pre-IND and 13 Named Platform-
generated drug programmes
+10 Exploratory stage programmes
Discovery
Preclinical
BEN-2293 - Atopic Dermatitis
BEN-8744 - Ulcerative Colitis
BEN-9160 - ALS
BEN- 28010 - Glioblastoma
✔Disease-agnostic
Clinical
Olumiant Image source: olumiant.com/hcp/rheumatoid-arthritis/dosing
STRATEGIC VALIDATION
Successful delivery on multi-target
long-term collaboration
AstraZeneca
Chronic kidney disease (CKD)
Idiopathic pulmonary fibrosis (IPF)
Heart failure
Systemic lupus erythematosus
CLINICAL & REGULATORY VALIDATION
US FDA DRUG APPROVED
The Benevolent Platform™
successfully discovered an FDA
approved treatment for COVID-19
Lilly
N=
O=S=O
ALWAYS DISPENSE W
MEDICATION QUIDE
NDC 0002-4180-30
Olumiant
(baricitinib) tablets
2 mg
30 tablets Lilly
Benevolent 22View entire presentation